Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.

Kaku, Kohei; Frederik Rasmussen, Mads; Nishida, Tomoyuki; Seino, Yutaka

doi:10.1111/j.2040-1124.2011.00128.x

Public

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.

Shared by NobleBlocks on Nov 30, 2011 • 12:00 AM UTC

Authors:

Kohei Kaku

Mads Frederik Rasmussen

Tomoyuki Nishida

Abstract

Aims/Introduction: We compared the safety and efficacy of liraglutide vs glibenclamide in patients with poorly controlled (HbA1c, 7.4-10.4%) type 2 diabetes. MATERIALS AND METHODS: Subjects were randomly assigned at a 1:2 ratio to receive 1-year treatment with glibenclamide 1.25-2.5 mg/day or lirag...

Subject

GLP‐1 receptor agonist

Liraglutide

Type 2 diabetes mellitus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!